Tolvaptan IR
Sponsors
Otsuka Pharmaceutical Development & Commercialization, Inc.
Conditions
Autosomal Dominant Polycystic Kidney Disease
Phase 2
Dose-finding Study of New Tolvaptan Formulation in Subjects With ADPKD
CompletedNCT01210560
Start: 2010-10-31End: 2011-06-30Updated: 2018-06-14
8-Week Study of Tolvaptan Dose Forms in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
CompletedNCT01451827
Start: 2011-10-31End: 2013-07-31Updated: 2018-09-27